July 2, 2004 — Continuous subcutaneous insulin infusion (CSII) improved glycemic control in children and adolescents with type 1 diabetes better than did multiple daily injection (MDI) with glargine, ...

Hoogma RPLM et al. (2005) Comparison of the effects of continuous subcutaneous insulin infusion (CSII) and NPH-based multiple daily insulin injections (MDI) on glycaemic control and quality of life: ...

This new study investigated and compared the incidence of disordered eating behavior (DEB) among 2 cohorts of patients with type 1 diabetes (T1D) treated with continuous-subcutaneous insulin infusion ...

The Diabetes Control and Complications Trial research group documented that low glycosylated hemoglobin (HbA1c) levels were associated with reduced onset and progression of microvascular complications ...

Patients with type 2 diabetes who were initially treated with multiple daily injections were assessed before and after switching to continuous subcutaneous insulin infusion. OPT2MISE was a multicenter ...

The effect of switching from multiple daily insulin injections to an insulin pump on insulin and other diabetic drug expenditures in type 2 diabetes. Continuous users of MDI therapy throughout the ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio Despite the lack of cost-effectiveness of ...

HealthDay News — For patients with type 2 diabetes and hemoglobin A1c (HbA1c) >8% following multiple daily injections (MDI), continuous subcutaneous insulin infusion (CSII) is associated with a ...

Novo Nordisk has received FDA approval for NovoLog (insulin aspart [rDNA origin] injection) for continuous subcutaneous insulin infusion (CSII) by external insulin pump in pediatric patients 4-18 ...

A review of published research from the University of Liege, Belgium, reveals a decline in the number of people experiencing allergic reactions to insulin. This is largely due to better purification ...

(MENAFN- Quintile Reports) The Global Continuous Subcutaneous Insulin Infusion Market was estimated at 743.05 million in 2025 and is projected to reach 1.89 billion by 2034 , reflecting a robust CAGR ...